Last reviewed · How we verify
ketorolac + bupivacaine
Ketorolac inhibits prostaglandin synthesis via COX inhibition to reduce pain and inflammation, while bupivacaine blocks sodium channels in nerve membranes to provide local anesthesia.
Ketorolac inhibits prostaglandin synthesis via COX inhibition to reduce pain and inflammation, while bupivacaine blocks sodium channels in nerve membranes to provide local anesthesia. Used for Acute postoperative pain management in pediatric patients, Local/regional anesthesia with systemic analgesia.
At a glance
| Generic name | ketorolac + bupivacaine |
|---|---|
| Sponsor | The Hospital for Sick Children |
| Drug class | NSAID + local anesthetic combination |
| Target | COX-1/COX-2 (ketorolac); voltage-gated sodium channels (bupivacaine) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
This is a combination product pairing a systemic NSAID (ketorolac) with a local anesthetic (bupivacaine). Ketorolac works centrally and peripherally by inhibiting cyclooxygenase enzymes, reducing prostaglandin-mediated pain and inflammation. Bupivacaine works locally by reversibly blocking voltage-gated sodium channels in nerve fibers, preventing action potential propagation and providing regional anesthesia. Together they provide multimodal analgesia for acute pain management.
Approved indications
- Acute postoperative pain management in pediatric patients
- Local/regional anesthesia with systemic analgesia
Common side effects
- Local injection site reactions
- Gastrointestinal upset (ketorolac)
- Systemic toxicity from bupivacaine (rare)
- Renal impairment (ketorolac)
Key clinical trials
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Postoperative Pain Will be Compared in Cholecystectomy Patients: Half Receiving TAP Block and Half Without it. (NA)
- Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy (PHASE2, PHASE3)
- Phase 2 Herniorrhaphy Study for Opioid Elimination (PHASE2)
- Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA (PHASE4)
- Comparison Of Clinical Outcomes of Intraperitoneal Bupivacaine Instillation Versus Placebo as Preemptive Analgesia in Patients Undergoing Open Appendectomy (PHASE1)
- R.E.C.K vs Exparel in Robotic Nephrectomy (PHASE3)
- Ultrasound-Guided PASC Block vs Femoral-Sciatic Nerve Block for Postoperative Analgesia After Total Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketorolac + bupivacaine CI brief — competitive landscape report
- ketorolac + bupivacaine updates RSS · CI watch RSS
- The Hospital for Sick Children portfolio CI